Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis
- Conditions
- Noninfectious Uveitis
- Interventions
- Registration Number
- NCT03207815
- Lead Sponsor
- Gilead Sciences
- Brief Summary
The primary objective of this study is to evaluate the efficacy of filgotinib versus placebo for the treatment of the signs and symptoms of noninfectious uveitis as measured by the percentage of participants failing treatment for active noninfectious uveitis by Week 24.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 74
-
Is diagnosed with active noninfectious intermediate-, posterior-, or pan-uveitis
-
Must have active uveitic disease at the Day 1/Baseline visit as defined by the presence of at least 1 of the following parameters in at least one eye despite 2 weeks of maintenance therapy with oral prednisone (≥ 10 mg/day to ≤ 60 mg/day) or an oral corticosteroid equivalent:
- Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion
- ≥ 2+ anterior chamber cells per the Standardization of Uveitis Nomenclature (SUN) criteria
- ≥ 2+ vitreous haze per the National Eye Institute/Standardization of Uveitis Nomenclature (NEI/SUN) criteria
-
No evidence of active tuberculosis (TB) or untreated latent TB
Key
- Participants with elevated intraocular pressures and/or severe glaucoma
- Confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to TB, cytomegalovirus (CMV), Human T-Lymphotropic Virus Type 1 (HTLV-1), Whipple's disease, Herpes Zoster virus (HZV), Lyme disease, toxoplasmosis and herpes simplex virus (HSV)
Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo to match filgotinib Participants will receive placebo to match filgotinib once daily for up to 52 weeks along with a standardized prednisone burst of 60 mg/day at Day 1/Baseline followed by a protocol-defined mandatory taper schedule up to Week 15. Filgotinib Filgotinib Participants will receive filgotinib 200 milligrams (mg) once daily for up to 52 weeks along with a standardized prednisone burst of 60 milligrams per day (mg/day) at Day 1/Baseline followed by a protocol-defined mandatory taper schedule up to Week 15. Placebo Prednisone Participants will receive placebo to match filgotinib once daily for up to 52 weeks along with a standardized prednisone burst of 60 mg/day at Day 1/Baseline followed by a protocol-defined mandatory taper schedule up to Week 15. Filgotinib Prednisone Participants will receive filgotinib 200 milligrams (mg) once daily for up to 52 weeks along with a standardized prednisone burst of 60 milligrams per day (mg/day) at Day 1/Baseline followed by a protocol-defined mandatory taper schedule up to Week 15.
- Primary Outcome Measures
Name Time Method Percentage of Participants Failing Treatment for Active NonInfectious Uveitis by Week 24 Week 6 through Week 24 Treatment failure was a participant meeting at least 1 of these criteria in at least 1 eye: New active, inflammatory lesions relative to Day 1/Baseline (all visits starting Week (Wk) 6); Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (change of Grade 0 to Grade 2+/Grade 0.5+ to Grade 3+) (all visits after Wk 6) relative to best state (RBS) achieved in Anterior Chamber (AC) cell grade (Standardization of Uveitis Nomenclature \[SUN\] criteria)\[AC cell grades range from 0 (0 cells) to 4+ (\>50 cells), higher scores=severe uveitis\]; Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (all visits after Wk 6) RBS achieved in Vitreous Haze (VH) grade (National Eye Institute \[NEI\]/SUN criteria)\[VH grades range from 0 (no evident VH) to 4+ (optic nerve head is obscured), higher scores=severe uveitis\]; Worsening of best corrected visual acuity (BCVA) by ≥15 letters RBS achieved (all visits starting Wk 6), measured by an eye chart, fewer correct letters=severe uveitis.
- Secondary Outcome Measures
Name Time Method Change in Vitreous Haze (VH) Grade in Each Eye (NEI/SUN Criteria), From Best State Achieved Prior to Week 6 to Week 52 or End of Treatment (EOT) Visit or Early Termination (ET) Prior to Week 6; Up to Week 52 or EOT or ET (maximum: 53 weeks) Grading of VH was based on the publication from the NEI which has also been adapted by the SUN working group. VH grades range from 0 (no evident VH) to 4+ (optic nerve head is obscured), with higher scores indicating greater severity of uveitis. A negative change from best state value obtained prior to Week 6 indicates improvement.
Time to Treatment Failure on or After Week 6 Week 6 through Week 52 Treatment failure was a participant meeting at least 1 of these criteria in at least 1 eye: New active, inflammatory lesions relative to Day 1/Baseline (all visits starting Wk 6); Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (change of Grade 0 to Grade 2+/Grade 0.5+ to Grade 3+) (all visits after Wk 6) relative to best state (RBS) achieved in AC cell grade (SUN criteria) \[AC cell grades range from 0 (0 cells) to 4+ (\>50 cells), higher scores=severe uveitis\]; Inability to achieve ≤Grade 0.5+ (at Wk 6) or 2-step increase (all visits after Wk 6) RBS achieved in VH grade (NEI/SUN criteria) \[VH grades range from 0 (no evident VH) to 4+ (optic nerve head is obscured), higher scores=severe uveitis\]; Worsening of BCVA by ≥15 letters RBS achieved (all visits starting Wk 6), measured by an eye chart, fewer correct letters=severe uveitis.
Change in Anterior Chamber (AC) Cell Grade in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET Prior to Week 6; Up to Week 52 or EOT or ET (maximum: 53 weeks) The number of AC cells observed within a 1 mm × 1 mm slit beam were recorded for each eye. The reported number was used to determine the grade according to the SUN criteria. AC cell grades range from 0 (0 cells in field) to 4+ (\>50 cells in field), with higher scores indicating more cells visible in the AC and greater severity of uveitis. A negative change from best state value obtained prior to Week 6 indicates improvement.
Plasma Concentration of Metabolite, GS-829845 Day 1 post dose, Weeks 4 and 6 predose, Week 12 post dose, Weeks 24, 36, 52 (EOT), ET at any time Change in Logarithm of the Minimal Angle of Resolution (logMAR) Best Corrected Visual Acuity (BCVA) in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET Prior to Week 6; Up to Week 52 or EOT or ET (maximum: 53 weeks) BCVA is the best possible vision that an eye can achieve with the set of glasses or contact lenses. A refraction test was performed to measure the appropriate lens strength to focus light on the retina. Using the appropriate corrective lenses based on that visit's refraction, participant's BCVA was measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. In the ETDRS system, 15 letters is equal to a change in 3 lines of visual acuity. If the participant is unable to read letters on a testing chart, visual acuity is described as ranging from ability to count fingers, recognize hand movements, or light perception. The smaller BVCA score indicates greater severity of uveitis. A positive change from best state value obtained prior to Week 6 indicates improvement.
Time to Development of Macular Edema in At Least One Eye on or After Week 6 Week 6 through Week 52 Time in weeks until the development of Macular edema or Week 52 or EOT or ET. Macular edema is determined by OCT and is defined as central retinal thickness ≥ 300 microns if using Cirrus machine, or ≥ 315 microns if using Spectralis machine.
Plasma Concentration of Filgotinib Day 1 post dose, Weeks 4 and 6 predose, Week 12 post dose, Weeks 24, 36, 52 (EOT), ET at any time Log Change in Central Retinal Thickness in Each Eye, From Best State Achieved Prior to Week 6 to Week 52 or EOT Visit or ET Prior to Week 6; Up to Week 52 or EOT or ET (maximum: 53 weeks) Central retinal thickness is measured by optical coherence tomography (OCT). Central retinal thickness is defined as the thickness of the retina in the center of the foveal pit (1 mm subfield). The larger central retinal thickness value indicates greater severity of uveitis. A negative change from best state value obtained prior to Week 6 indicates improvement.
Trial Locations
- Locations (24)
Metropolitan Eye Research and Surgery Institute
🇺🇸Palisades Park, New Jersey, United States
Texas Retina Associates - Fort Worth
🇺🇸Fort Worth, Texas, United States
Colorado Retina Associates PC
🇺🇸Golden, Colorado, United States
Lions Eye Institute
🇦🇺Nedlands, Western Australia, Australia
Illinois Retina Associates
🇺🇸Oak Park, Illinois, United States
Northwestern Medical Group
🇺🇸Chicago, Illinois, United States
Ophthalmic Consultants of Boston
🇺🇸Boston, Massachusetts, United States
Associated Retinal Consultants PC
🇺🇸Royal Oak, Michigan, United States
Wake Forest Baptist Medical Center
🇺🇸Winston-Salem, North Carolina, United States
Cleveland Clinic Foundation-Cole Eye Institute
🇺🇸Cleveland, Ohio, United States
Duke University Eye Center
🇺🇸Durham, North Carolina, United States
Oregon Health Science University-Casey Eye Institute
🇺🇸Portland, Oregon, United States
Mid Atlantic Retina
🇺🇸Philadelphia, Pennsylvania, United States
Foresight Studies, LLC
🇺🇸San Antonio, Texas, United States
Retina Consultants
🇨🇦Vancouver, Canada
university of Wisconsin-Madison
🇺🇸Madison, Wisconsin, United States
St. Franziskus Hospital
🇩🇪Münster, Germany
Hadassah Medical Center
🇮🇱Jerusalem, Israel
Auckland Eye
🇳🇿Remuera, New Zealand
Moorfields Eye Hospital NHS Foundation Trust
🇬🇧London, United Kingdom
Central Mancester Hospitals NHS Foundation Trust, Manchester Royal Eye Hospital
🇬🇧Manchester, United Kingdom
Eye Research Group Oxford, Oxford Eye Hospital
🇬🇧Oxford, United Kingdom
Stanford Byers Eye Institute
🇺🇸Palo Alto, California, United States
Royal Liverpool University Hospital
🇬🇧Liverpool, United Kingdom